Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

NEW YORK, Oct. 31, 2012 /PRNewswire-FirstCall/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

http://www.reportlinker.com/p01023647/Gastrointestinal-Disorders-Therapeutics-Market-to-2018---Novel-Agents-Targeting-Irritable-Bowel-Syndrome-IBS-Chronic-Constipation-CC-and-Ulcerative-Colitis-UC-to-Reinvigorate-the-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market", which provides insights into the gastrointestinal disorders therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. It provides in-depth analysis of the major diseases, comprising IBS, constipation, Crohn's disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

GBI Research's analysis shows that the gastrointestinal disorders therapeutics market is set to witness high generic competition in the forecast period, as major drugs used in the treatment of the aforementioned disorders are set to expire, resulting in declining revenues and allowing generics to enter the market. Nevertheless, the market will witness steady growth due to the anticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS, constipation, Crohn's disease and UC remains a key market driver.

Scope

- Data and analysis for the gastrointestinal disorders therapeutics markets in the leading geographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italy and Spain; Japan; and an overview of India, China and Australia

- Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010 and forecast to 2018

- Market data for the geographical and therapeutic landscapes, including size, share, annual cost of therapy, sales volume and treatment usage patterns for the diseased population, diagnosis population and prescription population

- Generic share in the global market and for each indication

- Key drivers and restraints that have had a significant impact on the market

- The competitive landscape of the global market, looking at key companies such as AstraZeneca, Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix

- Key M&A activity and licensing agreements that took place between 2010 and 2012

Reasons to buy

- Align product portfolios to the markets with high growth potential

- Build effective strategies to launch pipeline products by identifying potential geographies

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps

- Develop key strategic initiatives by studying top competitors' key strategies

- Device a more tailored country strategy by understanding the key drivers, barriers and market potential for each indication

- Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms producing safer and more efficacious FIC molecules

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 9

1.2 List of Figures 12

2 Gastrointestinal Disorders Therapeutics Market - Introduction 15

2.1 Overview 15

3 Global Gastrointestinal Disorders Therapeutics Market - Market Characterization 16

3.1 Market Forecasts 16

3.1.1 Branded and Generic Global Market Share 18

3.1.2 Annual Cost of Treatment 19

3.1.3 Treatment Usage Patterns 20

3.2 Drivers and Restraints for the Global Gastrointestinal Disorders Therapeutics Market 22

3.2.1 Market Drivers 22

3.2.2 Market Restraints 23

4 Gastrointestinal Disorders Therapeutics Market - Geographical Landscape 24

4.1 Revenue Analysis by Geography 24

4.2 The US 24

4.2.1 Revenue 24

4.2.2 Annual Cost of Treatment 26

4.2.3 Treatment Usage Patterns 27

4.3 Top Five Countries of Europe 29

4.3.1 Revenue 29

4.3.2 Revenue by Country 30

4.3.3 Annual Cost of Treatment 32

4.3.4 Treatment Usage Patterns 33

4.4 Japan 35

4.4.1 Revenue 35

4.4.2 Annual Cost of Treatment 37

4.4.3 Treatment Usage Patterns 38

4.5 Gastrointestinal Disorders Therapeutics Market India-Overview 40

4.5.1 Epidemiology 40

4.5.2 Clinical Trials 41

4.5.3 Drivers and Restraints 41

4.6 Gastrointestinal Disorders Therapeutics Market Australia-Overview 42

4.6.1 Epidemiology 42

4.6.2 Clinical Trials 43

4.6.3 Drivers and Restraints 43

4.7 Gastrointestinal Disorders Therapeutics Market China-Overview 44

4.7.1 Epidemiology 44

4.7.2 Clinical Trials 45

4.7.3 Drivers and Restraints 45

5 Global Gastrointestinal Disorders Therapeutics Market - Therapeutic Landscape 46

5.1 Global Irritable Bowel Syndrome Therapeutics Market Forecasts 46

5.1.1 Introduction 46

5.1.2 Treatment Flow Algorithm 47

5.1.3 Revenue 48

5.1.4 Revenue by Country 49

5.1.5 Branded vs. Generic Market Share 51

5.1.6 Annual Cost of Treatment 52

5.1.7 Treatment Usage Patterns 53

5.2 Drivers and Restraints for the Irritable Bowel Syndrome Therapeutics Market 55

5.2.1 Drivers for the Irritable Bowel Syndrome Therapeutics Market 55

5.2.2 Restraints for the Irritable Bowel Syndrome Therapeutics Market 55

5.3 Global Constipation Therapeutics Market Forecasts 56

5.3.1 Introduction 56

5.3.2 Treatment Flow Algorithm 57

5.3.3 Revenue 58

5.3.4 Revenue Analysis by Country 59

5.3.5 Branded vs. Generic Market Share 61

5.3.6 Annual Cost of Treatment 62

5.3.7 Treatment Usage Patterns 63

5.4 Drivers and Restraints for the Constipation Therapeutics Market 65

5.4.1 Drivers for Constipation Therapeutics Market 65

5.4.2 Restraints for Constipation Therapeutics Market 65

5.5 Global Crohn's Disease Therapeutics Market Forecasts 66

5.5.1 Introduction 66

5.5.2 Treatment Flow Algorithm 67

5.5.3 Revenue 68

5.5.4 Revenue by Country 69

5.5.5 Branded vs. Generic Market Share 71

5.5.6 Annual Cost of Treatment 72

5.5.7 Treatment Usage Patterns 73

5.6 Drivers and Restraints for the Crohn's Disease Therapeutics Market 75

5.6.1 Drivers for the Crohn's Disease Therapeutics Market 75

5.6.2 Restraints for the Crohn's Disease Therapeutics Market 75

5.7 Global Ulcerative Colitis Therapeutics Market Forecasts 76

5.7.1 Introduction 76

5.7.2 Treatment Flow Algorithm 77

5.7.3 Revenue 78

5.7.4 Revenue by Country 79

5.7.5 Branded vs. Generic Market Share 81

5.7.6 Annual Cost of Treatment 82

5.7.7 Treatment Usage Patterns 83

5.8 Drivers and Restraints for the Ulcerative Colitis Therapeutics Market 85

5.8.1 Drivers for the Ulcerative Colitis Therapeutics Market 85

5.8.2 Restraints for the Ulcerative Colitis Therapeutics Market 85

5.9 Global Gastroesophageal Reflux Disease Therapeutics Market Forecasts 86

5.9.1 Introduction 86

5.9.2 Treatment Flow Algorithm 87

5.9.3 Revenue 89

5.9.4 Revenue by Country 91

5.9.5 Branded vs. Generic Market Share 93

5.9.6 Annual Cost of Treatment 94

5.9.7 Treatment Usage Patterns 95

5.10 Drivers and Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 97

5.10.1 Drivers for the Gastroesophageal Reflux Disease Therapeutics Market 97

5.10.2 Restraints for the Gastroesophageal Reflux Disease Therapeutics Market 97

5.11 Global Peptic Ulcer Disease Therapeutics Market Forecasts 98

5.11.1 Introduction 98

5.11.2 Treatment Flow Algorithm 99

5.11.3 Revenue 100

5.11.4 Revenue Analysis by Country 102

5.11.5 Generic vs. Branded Market Share 104

5.11.6 Annual Cost of Treatment 105

5.11.7 Treatment Usage Patterns 106

5.12 Drivers and Restraints for the Peptic Ulcer Disease Therapeutics Market 108

5.12.1 Drivers for Peptic Ulcer Disease Therapeutics Market 108

5.12.2 Restraints for Peptic Ulcer Disease Therapeutics Market 108

6 Global Gastrointestinal Disorders Therapeutics Market - Pipeline Analysis 109

6.1 Summary 109

6.2 Research and Development Pipeline by Phase 109

6.3 Research and Development Pipeline by Indication 110

6.4 Irritable Bowel Syndrome: Research and Development Pipeline 111

6.4.1 Pipeline by Phase 111

6.5 Constipation: Research and Development Pipeline 112

6.5.1 Research and Development Pipeline by Phase 112

6.6 Crohn's Disease: Research and Development Pipeline 113

6.6.1 Research and Development Pipeline by Phase 113

6.7 Ulcerative Colitis: Research and Development Pipeline 114

6.7.1 Research and Development Pipeline by Phase 114

6.8 Gastroesophageal Reflux Disease: Research and Development Pipeline 115

6.8.1 Research and Development Pipeline by Phase 115

6.9 Peptic Ulcer Disease: Research and Development Pipeline 116

6.9.1 Research and Development Pipeline by Phase 116

6.10 Promising Pipeline Molecules 117

6.10.1 Linzess (linaclotide) 118

6.10.2 Xifaxan (rifaximin) 120

6.10.3 Relistor (methylnaltrexone) 121

6.10.4 Humira (adalimumab) 123

6.10.5 Uceris (budesonide) 123

6.10.6 Plecanatide 124

6.10.7 Vedolizumab (MLN0002) 125

6.10.8 Naloxegol (NKTR-118) 126

6.10.9 Simponi (golimumab) 127

6.10.10 Asimadoline 128

6.10.11 Traficet-EN (GSK-1605786) 129

6.10.12 Cobiprostone 130

7 Global Gastrointestinal Disorders Therapeutics Market - Competitive Landscape 131

7.1 Market Share Analysis 131

7.2 Profiles of Major Companies 132

7.2.1 AstraZeneca 132

7.2.2 Takeda Pharmaceutical Company 133

7.2.3 Johnson & Johnson 135

7.2.4 Eisai Co., Ltd. 136

7.2.5 Abbott Laboratories 137

7.2.6 Shire 138

7.2.7 Salix Pharmaceuticals 139

8 Global Gastrointestinal Disorders Therapeutics Market - Strategic Consolidations 142

8.1 Overview 142

8.2 Mergers and Acquisitions 143

8.2.1 Major Mergers and Acquisitions Deals 143

8.2.2 Segmentation by Geography 146

8.2.3 Segmentation by Deal Value 147

8.2.4 Segmentation by Year 148

8.3 Licensing Deals 149

8.3.1 Major Licensing Deals 149

8.3.2 Segmentation by Geography 152

8.3.3 Segmentation by Deal Value 153

8.3.4 Segmentation by Year 154

8.4 Co-development/Co-marketing Deals 155

8.4.1 Major Co-development/Co-marketing Deals 155

8.4.2 Segmentation by Geography 158

8.4.3 Segmentation by Deal Value 159

8.4.4 Segmentation by Year 160

9 Gastrointestinal Disorders Therapeutics Market - Appendix 161

9.1 Abbreviations 161

9.2 Market Definitions 162

9.3 Bibliography 162

9.4 Research Methodology 166

9.4.1 Secondary Research 166

9.4.2 Primary Research 166

9.4.3 Expert Panel Validation 167

9.4.4 Section-wise Research Methodology 167

9.5 Therapeutic Landscape 167

9.5.2 Market Size by Geography 169

9.6 Geographical Landscape 170

9.7 Pipeline Analysis 170

9.8 Competitive Landscape 170

9.9 Strategic Consolidations 170

9.10 Contact Us 170

9.11 Disclaimer 171

1.1 List of Tables

Table 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004–2011 16

Table 2: Gastrointestinal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2011–2018 16

Table 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 19

Table 4: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 19

Table 5: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2004–2011 20

Table 6: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2011–2018 21

Table 7: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004–2011 24

Table 8: Gastrointestinal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2011–2018 24

Table 9: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2004–2011 26

Table 10: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2011–2018 26

Table 11: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2004–2011 27

Table 12: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2011–2018 28

Table 13: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004–2011 29

Table 14: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecast, ($bn), 2011–2018 29

Table 15: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2004–2011 30

Table 16: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($bn), 2011–2018 31

Table 17: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004–2011 32

Table 18: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011–2018 32

Table 19: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2004–2011 33

Table 20: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2011–2018 34

Table 21: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004–2011 35

Table 22: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2011–2018 35

Table 23: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004–2011 37

Table 24: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2011–2018 37

Table 25: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2004–2011 38

Table 26: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2011–2018 39

Table 27: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), India, 2011 40

Table 28: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, India, 2012 41

Table 29: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), Australia, 2011 42

Table 30: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, Australia, 2012 43

Table 31: Gastrointestinal Disorders Therapeutics Market, Diseased Population ('000), China, 2011 44

Table 32: Gastrointestinal Disorders Therapeutics Market, Pipeline Molecules, China, 2012 45

Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2011 48

Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 48

Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 49

Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue Forecast by Country ($m), 2011–2018 50

Table 37: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 52

Table 38: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 52

Table 39: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2011 53

Table 40: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011–2018 54

Table 41: Constipation Therapeutics Market, Global, Revenue ($m), 2004–2011 58

Table 42: Constipation Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 58

Table 43: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 59

Table 44: Constipation Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011–2018 60

Table 45: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 62

Table 46: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 62

Table 47: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2011 63

Table 48: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011–2018 64

Table 49: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 68

Table 50: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 68

Table 51: Crohn's Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 69

Table 52: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011–2018 70

Table 53: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 72

Table 54: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 72

Table 55: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004–2011 73

Table 56: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2011–2018 74

Table 57: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004–2011 78

Table 58: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 78

Table 59: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 79

Table 60: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecast by Country ($m), 2011–2018 80

Table 61: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 82

Table 62: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 82

Table 63: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2011 83

Table 64: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011–2018 84

Table 65: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 89

Table 66: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 89

Table 67: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 91

Table 68: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011–2018 92

Table 69: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 94

Table 70: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 94

Table 71: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2011 95

Table 72: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011–2018 96

Table 73: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004–2011 100

Table 74: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2011–2018 100

Table 75: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2011 102

Table 76: Peptic Ulcer Disease Therapeutics Market, Global, Revenue Forecasts by Country ($m), 2011–2018 103

Table 77: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2011 105

Table 78: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2011–2018 105

Table 79: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2011 106

Table 80: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2011–2018 107

Table 81: Gastrointestinal Disorders Therapeutics Market, Global, NDA-filed Molecules, 2012 117

Table 82: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase III Molecules, 2012 117

Table 83: Gastrointestinal Disorders Therapeutics Market, Global, Promising Phase II Molecules, 2012 117

Table 84: Gastrointestinal Disorders Therapeutics Market, Global, Major M&A Deals, 2010–Mid 2012 143

Table 85: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography, 2010–Mid-2012 146

Table 86: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2010–Mid-2012 147

Table 87: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010–Mid-2012 148

Table 88: Gastrointestinal Disorders Therapeutics Market, Global, Major Licensing Deals, 2010–Mid-2012 149

Table 89: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography, 2010–Mid-2012 152

Table 90: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value, 2010–Mid 2012 153

Table 91: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010–Mid-2012 154

Table 92: Gastrointestinal Disorders Therapeutics Market, Global, Major Co-development/Co-Marketing Deals, 2010–Mid-2012 155

Table 93: Gastrointestinal Disorders Therapeutics Market, Global, Co-development/Marketing Deals by Geography, 2010–Mid-2012 158

Table 94: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value, 2010–Mid-2012 159

Table 95: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010–Mid-2012 160

1.2 List of Figures

Figure 1: Gastrointestinal Disorders Therapeutics Market, Global, Revenue ($bn), 2004–2018 16

Figure 2: Gastrointestinal Disorders Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 18

Figure 3: Gastrointestinal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 19

Figure 4: Gastrointestinal Disorders Therapeutics Market, Global, Treatment Usage Pattern (Million), 2004–2018 20

Figure 5: Gastrointestinal Disorders Therapeutics Market, Global, Market Drivers and Restraints 22

Figure 6: Gastrointestinal Disorders Therapeutics Market, The US, Revenue ($bn), 2004–2018 24

Figure 7: Gastrointestinal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2004–2018 26

Figure 8: Gastrointestinal Disorders Therapeutics Market, The US, Treatment Usage Patterns ('000), 2004–2018 27

Figure 9: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004–2018 29

Figure 10: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2004–2018 30

Figure 11: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004–2018 32

Figure 12: Gastrointestinal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Million), 2004–2018 33

Figure 13: Gastrointestinal Disorders Therapeutics Market, Japan, Revenue ($bn), 2004–2018 35

Figure 14: Gastrointestinal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004–2018 37

Figure 15: Gastrointestinal Disorders Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2004–2018 38

Figure 16: Irritable Bowel Syndrome Therapeutics Market, Global, Breakdown of Irritable Bowel Syndrome Subtypes(%), 2012 46

Figure 17: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Flow Algorithm for Irritable Bowel Syndrome 47

Figure 18: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2004–2018 48

Figure 19: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 49

Figure 20: Irritable Bowel Syndrome Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 51

Figure 21: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 52

Figure 22: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2018 53

Figure 23: Irritable Bowel Syndrome Therapeutics Market, Global, Market Drivers and Restraints 55

Figure 24: Constipation Therapeutics Market, Global, Treatment Flow Algorithm for Constipation 57

Figure 25: Constipation Therapeutics Market, Global, Revenue ($m), 2004–2018 58

Figure 26: Constipation Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 59

Figure 27: Constipation Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 61

Figure 28: Constipation Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 62

Figure 29: Constipation Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2018 63

Figure 30: Constipation Therapeutics Market, Global, Market Drivers and Restraints 65

Figure 31: Crohn's Disease Therapeutics Market, Global, Treatment Flow Algorithm for Crohn's Disease 67

Figure 32: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 68

Figure 33: Crohn's Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 69

Figure 34: Crohn's Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 71

Figure 35: Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 72

Figure 36: Crohn's Disease Therapeutics Market, Global, Treatment Usage Patterns, 2004–2018 73

Figure 37: Crohn's Disease Therapeutics Market, Global, Market Drivers and Restraints 75

Figure 38: Ulcerative Colitis Therapeutics Market, Global, Treatment Flow Algorithm for Ulcerative Colitis 77

Figure 39: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2004–2018 78

Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 79

Figure 41: Ulcerative Colitis Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 81

Figure 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 82

Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2018 83

Figure 44: Ulcerative Colitis Therapeutics Market, Global, Market Drivers and Restraints 85

Figure 45: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow Algorithm for Self and Primary-care Treatment 87

Figure 46: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Flow Algorithm for Secondary-care Treatment 88

Figure 47: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 89

Figure 48: Gastroesophageal Reflux Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 91

Figure 49: Gastroesophageal Reflux Disease Therapeutics Market, Global, Branded vs. Generic Market Share (%), 2011 93

Figure 50: Gastroesophageal Reflux Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 94

Figure 51: Gastroesophageal Reflux Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2018 95

Figure 52: Gastroesophageal Reflux Disease Therapeutics Market, Market Drivers and Restraints 97

Figure 53: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Flow Algorithm 99

Figure 54: Peptic Ulcer Disease Therapeutics Market, Global, Revenue ($m), 2004–2018 100

Figure 55: Peptic Ulcer Disease Therapeutics Market, Global, Revenue by Country ($m), 2004–2018 102

Figure 56: Peptic Ulcer Disease Therapeutics Market, Global, Generic vs. Branded Market Share (%) 104

Figure 57: Peptic Ulcer Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2004–2018 105

Figure 58: Peptic Ulcer Disease Therapeutics Market, Global, Treatment Usage Patterns ('000), 2004–2018 106

Figure 59: Peptic Ulcer Disease Therapeutics Market, Market Drivers and Restraints 108

Figure 60: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Phase, (%), 2012 109

Figure 61: Gastrointestinal Disorders Therapeutics Market, Global, Pipeline by Indication, (%), 2012 110

Figure 62: Gastrointestinal Disorders Therapeutics Market, Global, IBS Pipeline by Phase, (%), 2012 111

Figure 63: Gastrointestinal Disorders Therapeutics Market, Global, Constipation Pipeline by Phase, (%), 2012 112

Figure 64: Gastrointestinal Disorders Therapeutics Market, Global, Crohn's Disease Pipeline by Phase, (%), 2012 113

Figure 65: Gastrointestinal Disorders Therapeutics Market, Global, Ulcerative Colitis Pipeline by Phase, (%), 2012 114

Figure 66: Gastrointestinal Disorders Therapeutics Market, Global, GERD Pipeline by Phase, (%), 2012 115

Figure 67: Gastrointestinal Disorders Therapeutics Market, Global, Peptic Ulcer Disease Pipeline by Phase, (%), 2012 116

Figure 68: Gastrointestinal Disorders Therapeutics Market, Global, Market Share by Company, %, 2011 131

Figure 69: Gastrointestinal Disorders Therapeutics Market, AstraZeneca, SWOT Analysis 132

Figure 70: Gastrointestinal Disorders Therapeutics Market, Takeda Pharmaceutical Company, SWOT Analysis 134

Figure 71: Gastrointestinal Disorders Therapeutics Market, Johnson & Johnson, SWOT Analysis 135

Figure 72: Gastrointestinal Disorders Therapeutics Market, Eisai Company Limited, SWOT Analysis 136

Figure 73: Gastrointestinal Disorders Therapeutics Market, Abbott Laboratories, SWOT Analysis 137

Figure 74: Gastrointestinal Disorders Therapeutics Market, Shire, SWOT Analysis 138

Figure 75: Gastrointestinal Disorders Therapeutics Market, Salix Pharmaceuticals, SWOT Analysis 140

Figure 76: Gastrointestinal Disorders Therapeutics Market, Deals by Type, 2010–Mid-2012 142

Figure 77: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Geography, 2010–Mid-2012 146

Figure 78: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2010–Mid-2012 147

Figure 79: Gastrointestinal Disorders Therapeutics Market, Global, M&A Deals by Year, 2010–Mid-2012 148

Figure 80: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Geography, 2010–Mid-2012 152

Figure 81: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m), 2010–Mid-2012 153

Figure 82: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Year, 2010–Mid-2012 154

Figure 83: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by Geography, 2010–Mid-2012 158

Figure 84: Gastrointestinal Disorders Therapeutics Market, Global, Licensing Deals by Value ($m), 2010–Mid-2012 159

Figure 85: Gastrointestinal Disorders Therapeutics Market, Global, Co-development Deals by Year, 2010–Mid 2012 160

Figure 86: GBI Research Market Forecasting Model 169

Companies Mentioned

AstraZeneca

Takeda Pharmaceutical Company

Johnson & Johnson

Eisai Co., Ltd.

Abbott Laboratories

Shire

Salix Pharmaceuticals

To order this report:

Therapy Industry: Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker